What Is AOD 9604?
The fat-burning fragment of Human Growth Hormone — isolated to deliver metabolic benefits without the side effects of full HGH.
AOD 9604 (Advanced Obesity Drug 9604) is a synthetic peptide consisting of amino acids 177–191 from the C-terminal region of Human Growth Hormone. It was originally developed by Monash University in Australia specifically to isolate the fat-metabolizing properties of HGH — without the insulin resistance, tissue overgrowth, and other side effects associated with full HGH administration.
The key insight behind AOD 9604 is that HGH's lipolytic (fat-burning) activity is contained within a specific fragment of the molecule — and that fragment can be isolated and used independently. The result is a peptide that activates the same fat-burning pathways as HGH while leaving the growth-promoting and insulin-disrupting mechanisms of full HGH entirely untouched.
AOD 9604 completed Phase 2 clinical trials for obesity treatment — giving it one of the more advanced clinical development histories of any peptide currently used in the functional medicine space. While it was ultimately not commercialized as a pharmaceutical, the clinical data generated provides a meaningful evidence base for its safety and efficacy profile.
Full HGH stimulates fat burning but also promotes tissue growth, can cause insulin resistance, and suppresses natural GH production via negative feedback. AOD 9604 delivers the lipolytic benefits of HGH with none of these concerns — it does not affect IGF-1 levels, does not promote abnormal tissue growth, and does not interfere with insulin sensitivity. It's the targeted extraction of one specific HGH mechanism.
How Does AOD 9604 Work?
Four mechanisms explain AOD 9604's fat loss and metabolic effects.
AOD 9604 directly stimulates lipolysis — the breakdown of stored fat into free fatty acids for energy use. It activates beta-3 adrenergic receptors in fat tissue, mimicking the fat-burning signal of HGH without requiring full HGH administration. This is the primary mechanism driving its fat loss effects.
Simultaneously, AOD 9604 inhibits lipogenesis — the process by which the body converts carbohydrates and other substrates into new fat stores. This dual action (more fat burning + less fat storage) creates a more favorable metabolic environment than lipolysis stimulation alone.
An unexpected finding from AOD 9604 research is its effect on cartilage and bone tissue. Studies have demonstrated regenerative effects on osteoarthritis-damaged cartilage — making AOD 9604 relevant beyond pure fat loss, particularly for aging adults dealing with joint degeneration alongside metabolic concerns.
Unlike full HGH, AOD 9604 does not stimulate IGF-1 production and does not cause insulin resistance. This is the critical safety advantage — the metabolic concerns that limit long-term HGH use are absent with AOD 9604, making it appropriate for extended protocols.
What Is AOD 9604 Used For?
From targeted fat loss to joint health — AOD 9604 has a broader application profile than its name suggests.
- Targeted Fat Loss & Body CompositionThe primary application. AOD 9604 is particularly effective for stubborn fat deposits — the visceral and subcutaneous fat that resists diet and exercise interventions. Particularly relevant for adults experiencing the age-related metabolic slowdown that makes fat loss progressively harder after 40.
- Metabolic Rate EnhancementBeyond direct lipolysis, AOD 9604 supports overall metabolic rate — relevant for anyone experiencing the metabolic deceleration associated with aging, thyroid changes, or reduced physical activity.
- Joint & Cartilage HealthThe cartilage regeneration data from AOD 9604 studies makes it a relevant compound for osteoarthritis, joint pain, and age-related cartilage degeneration — particularly when these concerns coincide with body composition goals.
- GLP-1 ComplementAOD 9604 is increasingly used alongside GLP-1 medications (semaglutide, tirzepatide) — where GLP-1 drives appetite suppression and AOD 9604 amplifies the lipolytic response. A synergistic combination for those already on a GLP-1 protocol seeking to maximize fat loss outcomes.
- Post-Diet Metabolic MaintenanceAfter significant weight loss, metabolic adaptation (the "set point" response) makes maintaining results difficult. AOD 9604 supports the metabolic rate needed to sustain body composition improvements during the maintenance phase.
Why AOD 9604 Instead of HGH?
The targeted approach beats the broad approach for most adults seeking fat loss without the risks of full HGH.
| Feature | AOD 9604 | Full HGH |
|---|---|---|
| Fat burning (lipolysis) | ✅ Strong — primary mechanism AOD wins | ✅ Yes — but indirect |
| IGF-1 stimulation | ✅ None — no growth effects Safer | ❌ Significant — drives tissue growth |
| Insulin sensitivity | ✅ Not affected Safer | ❌ Can cause insulin resistance |
| Natural GH suppression | ✅ Does not suppress Safer | ❌ Suppresses natural production |
| Joint/cartilage benefit | ✅ Demonstrated | ⚠️ Some benefit but via IGF-1 |
| Cost | ✅ Significantly lower Accessible | ❌ High — $500–2000+/month |
| Legal status (US) | Research compound — off-label | Schedule III controlled substance |
| Best for | Fat loss, body comp, joint health | Clinical GH deficiency |
InformedPeptides may earn a commission on purchases made through affiliate links on this page. This never influences our editorial content or recommendations. We only recommend sources we have independently evaluated.
How to Use AOD 9604
Two primary protocols — fasted timing is critical for both.
AOD 9604 must be administered in a fasted state — food intake, particularly carbohydrates, blunts the lipolytic response significantly. Administer at least 30–60 minutes before eating, and ideally 2+ hours after your last meal. Morning fasted injection is the most common and reliable protocol.
AOD 9604 in a Body Composition Stack
AOD 9604 stacks naturally with compounds that address the metabolic and structural dimensions of body composition.
- +AOD 9604 + Semaglutide / Tirzepatide — The most powerful fat loss combination available. GLP-1 medications suppress appetite and reduce caloric intake; AOD 9604 amplifies the lipolytic response to ensure fat is the primary fuel source during the caloric deficit. Together they address both the intake (GLP-1) and expenditure (AOD 9604) sides of the energy equation.
- +AOD 9604 + 5-Amino-1MQ — A targeted metabolic stack. 5-Amino-1MQ inhibits NNMT to preserve NAD+ and reduce fat cell formation; AOD 9604 directly stimulates lipolysis. Together they address fat loss at the cellular energy level (5-Amino-1MQ) and the hormonal signaling level (AOD 9604) simultaneously.
- +AOD 9604 + BPC-157 — For adults whose body composition goals are complicated by joint pain or injury. AOD 9604 drives the fat loss; BPC-157 repairs the tissue damage that makes exercise difficult. Addressing both barriers simultaneously produces better adherence and better outcomes than tackling either alone.
- +AOD 9604 + Sermorelin — AOD 9604 provides targeted fat-burning from the HGH C-terminal fragment; Sermorelin restores the full pulsatile GH release that drives body composition, sleep, and recovery. Together they address GH-related body composition from two complementary angles without the risks of full HGH supplementation.
Frequently Asked Questions
Results vary significantly based on diet, exercise, and individual metabolic factors. Clinical trials showed meaningful fat reduction compared to placebo over 12-week periods. AOD 9604 is not a substitute for caloric management — it amplifies fat loss in the context of a reasonable nutrition and exercise protocol. Expect meaningful body composition improvement over 12–16 weeks, particularly in stubborn areas like visceral and lower body fat.
No — this is one of AOD 9604's key advantages over full HGH. Clinical trials specifically confirmed that AOD 9604 does not affect blood glucose or insulin sensitivity, making it appropriate for use in patients with metabolic syndrome, pre-diabetes, or those on GLP-1 medications where insulin dynamics are already being managed.
Oral formulations of AOD 9604 exist and are used clinically, though subcutaneous injection produces more reliable bioavailability. Oral AOD 9604 has some evidence of efficacy — particularly for joint/cartilage applications — but the lipolytic response is generally considered stronger with injectable administration. Discuss delivery preferences with your provider.
Phase 2 clinical trials found AOD 9604 to be well-tolerated with a clean safety profile over the trial duration. Unlike full HGH, there are no concerns about IGF-1 elevation, insulin resistance, or natural GH suppression with extended use. Standard practice is 12–16 week protocols with periodic breaks, though some practitioners use longer continuous protocols under monitoring.
This page is for educational purposes only and does not constitute medical advice. AOD 9604 is not FDA-approved for any indication. Always consult a qualified, licensed healthcare provider before beginning any peptide protocol. InformedPeptides.com and its authors are not liable for actions taken based on the content of this page.